Skip to main content

Phesgo Side Effects

Generic name: hyaluronidase / pertuzumab / trastuzumab

Medically reviewed by Last updated on Aug 18, 2022.

Note: This document contains side effect information about hyaluronidase / pertuzumab / trastuzumab. Some dosage forms listed on this page may not apply to the brand name Phesgo.

Applies to hyaluronidase / pertuzumab / trastuzumab: subcutaneous solution.


Subcutaneous route (Solution)

CardiomyopathyPertuzumab/trastuzumab/hyaluronidase-zzxf administration can result in subclinical and clinical cardiac failure manifesting as congesting heart failure, and decreased LVEF, with greatest risk when administered concurrently with anthracyclines. Evaluate cardiac function prior to and during treatment. Discontinue pertuzumab/trastuzumab/hyaluronidase-zzxf for cardiomyopathy.Embryo-fetal ToxicityExposure to pertuzumab/trastuzumab/hyaluronidase-zzxf can result in embryo-fetal death and birth defects. Advise patients of these risks and the need for effective contraception.Pulmonary ToxicityDiscontinue pertuzumab/trastuzumab/hyaluronidase-zzxf for anaphylaxis, angioedema, interstitial pneumonitis, or acute respiratory distress syndrome.

Serious side effects of Phesgo

Along with its needed effects, hyaluronidase / pertuzumab / trastuzumab may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor or nurse immediately if any of the following side effects occur while taking hyaluronidase / pertuzumab / trastuzumab:

More common

  • Black, tarry stools
  • bladder pain
  • bleeding, blistering, burning, coldness, discoloration of the skin, feeling of pressure, hives, infection, inflammation, itching, lumps, numbness, pain, rash, redness, scarring, soreness, stinging, swelling, tenderness, tingling, ulceration, or warmth at the injection site
  • bloody or cloudy urine
  • body aches or pain
  • burning, crawling, itching, numbness, prickling, "pins and needles", or tingling feelings
  • chest pain or tightness
  • chills
  • cough
  • cracked lips
  • decreased urine
  • diarrhea
  • difficult, burning, or painful urination
  • difficult or labored breathing
  • difficulty swallowing
  • dry mouth
  • ear congestion
  • fever
  • frequent urge to urinate
  • general feeling of discomfort or illness
  • headache
  • increased thirst
  • irregular heartbeat
  • joint pain
  • lack or loss of strength
  • loss of appetite
  • loss of voice
  • lower back or side pain
  • mood changes
  • muscle pain or cramps
  • nausea
  • nosebleed
  • numbness or tingling in the hands, feet, or lips
  • pale skin
  • redness, swelling, pain of the skin
  • runny or stuffy nose
  • scaling of the skin on the hands and feet
  • seizures
  • shivering
  • sneezing
  • sore throat
  • sores, ulcers, or white spots on the lips, tongue, or inside the mouth
  • sweating
  • swelling of the hands, ankles, feet, or lower legs
  • trouble sleeping
  • unusual bleeding or bruising
  • unusual tiredness or weakness
  • vomiting

Less common


  • Chest discomfort
  • dilated neck veins
  • thickening of bronchial secretions
  • weight gain

Incidence not known

  • Agitation
  • bleeding gums
  • confusion
  • decreased awareness or responsiveness
  • depression
  • hostility
  • irritability
  • joint stiffness or swelling
  • loss of consciousness
  • lower back, side, or stomach pain
  • mood or mental changes
  • muscle twitching
  • pinpoint red spots on the skin
  • severe sleepiness
  • stomach cramps
  • tremor
  • unusual drowsiness, dullness, or feeling of sluggishness

Other side effects of Phesgo

Some side effects of hyaluronidase / pertuzumab / trastuzumab may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.

Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

More common

  • Belching
  • bleeding after defecation
  • bone pain
  • change in or loss of taste
  • constipation
  • difficulty in moving
  • discoloration of the nails
  • dry eye or skin
  • feeling of warmth
  • heartburn
  • increased tearing of the eye
  • indigestion
  • pain and redness of the skin at the place of radiation treatment
  • redness of the face, neck, arms and occasionally, upper chest
  • stomach discomfort or upset
  • thinning or loss of hair
  • uncomfortable swelling around the anus

For Healthcare Professionals

Applies to hyaluronidase / pertuzumab / trastuzumab: subcutaneous solution.


Very common (10% or more): Hemoglobin low (90%), absolute lymphocytes low (89%), leukocyte count low (82%), neutrophils low (68%), anemia (36%), platelets low (27%), neutropenia (22%)

Common (1% to 10%): Leukopenia, febrile neutropenia[Ref]


Common (1% to 10%): Hypersensitivity[Ref]


Common (1% to 10%): Influenza-like illness[Ref]


Very common (10% or more): Radiation skin injury (19%), injection site reaction (15%), procedural pain (13%)

Common (1% to 10%): Injection site pain[Ref]


Very common (10% or more): Myalgia (25%), arthralgia (24%), pack pain (10%)

Common (1% to 10%): Bone pain, pain in extremity, muscle spasms, musculoskeletal pain[Ref]


Common (1% to 10%): Lacrimation increased, dry eye[Ref]


Very common (10% or more): Decreased appetite (17%), potassium low (17%), albumin low (16%), potassium high (13%), sodium low (13%), weight loss (11%)

Common (1% to 10%): Hypokalemia, glucose low, sodium high[Ref]


Very common (10% or more): Insomnia (17%)[Ref]


Common (1% to 10%): Urinary tract infection[Ref]


Very common (10% or more): Alanine aminotransferase high (58%), aspartate aminotransferase high (50%)

Common (1% to 10%): Bilirubin high


Very common (10% or more): Cough (15%), epistaxis (12%), upper respiratory infection (11%), dyspnea (10%)

Common (1% to 10%): Rhinorrhea, nasopharyngitis, paronychia

Frequency not reported: Dyspnea, interstitial pneumonitis, pulmonary infiltrates, pleural effusions, non-cardiogenic pulmonary edema, pulmonary insufficiency/hypoxia, acute respiratory distress syndrome, pulmonary fibrosis, exacerbation of chemotherapy-induced neutropenia[Ref]


Very common (10% or more): Asthenia (31%), fatigue (29%), pyrexia (13%)

Common (1% to 10%): Edema peripheral, malaise

Frequency not reported: Embryofetal toxicity[Ref]

Nervous system

Very common (10% or more): Dysgeusia (17%), headache (17%), peripheral sensory neuropathy (16%), peripheral neuropathy (12%), dizziness (13%), paresthesia (10%)[Ref]


Very common (10% or more): Creatinine high (84%)[Ref]


Very common (10% or more): Hot flush (12%), left ventricular cardiac dysfunction (LVEF)

Common (1% to 10%): Ejection fraction decreased

Frequency not reported: Hypertension, arrhythmias, left ventricular cardiac dysfunction, disabling cardiac failure, cardiomyopathy, cardiac death[Ref]


Very common (10% or more): Alopecia (77%), rash (16%), dry skin (15%)

Common (1% to 10%): Nail discoloration, erythema, dermatitis, nail disorder, palmar-plantar erythrodysesthesia syndrome

Uncommon (0.1% to 1%): Pruritus[Ref]


Very common (10% or more): Nausea (60%), diarrhea (60%), stomatitis (25%), constipation (22%), vomiting (20%), mucosal inflammation (15%), dyspepsia (14%)

Common (1% to 10%): Hemorrhoids, abdominal pain, abdominal pain upper[Ref]

More about Phesgo (hyaluronidase / pertuzumab / trastuzumab)

Patient resources

Professional resources

Related treatment guides


1. "Product Information. Phesgo (hyaluronidase / pertuzumab / trastuzumab)." Genentech (2020):

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.